Cells, methods, composition and immunotherapeutic target, and uses thereof in the treatment of malignant tumors

Abstract

The present application relates to an amino acid sequence of an scFv capable of recognizing the LILRB1 antigen, comprising (a) a heavy chain variable region (VH) comprising complementarity determining regions (CDRs), wherein CDR1, CDR2, and CDR3 of the VH region comprise the amino acid sequences of SEQ ID NO: 1, 2, 3, respectively, or a variant having at least 85% sequence identity thereto, and (b) a light chain variable region (VL), wherein CDR1, CDR2, and CDR3 of the VL region comprise the amino acid sequences of SEQ ID NO: 4, 5, 6, respectively, or a variant having at least 85% sequence identity thereto. The application also relates to a T lymphocyte that expresses a chimeric antigen receptor (CAR) on the cell surface, the CAR comprising an antigen-binding domain; a hinge domain; a transmembrane domain; and an intracellular domain; which CAR is directed against the LILRB1 antigen and methods, compositions and immunotherapeutic target for use in anticancer treatment.